MARCAINE SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

Dostupno od:

CARESTREAM HEALTH CANADA COMPANY

ATC koda:

N01BB51

INN (International ime):

BUPIVACAINE, COMBINATIONS

Doziranje:

5MG; 0.0091MG

Farmaceutski oblik:

SOLUTION

Sastav:

BUPIVACAINE HYDROCHLORIDE 5MG; EPINEPHRINE BITARTRATE 0.0091MG

Administracija rute:

BLOCK/INFILTRATION

Jedinice u paketu:

50X1.8ML

Tip recepta:

Ethical

Područje terapije:

LOCAL ANESTHETICS

Proizvod sažetak:

Active ingredient group (AIG) number: 0231290002; AHFS:

Status autorizacije:

CANCELLED POST MARKET

Datum autorizacije:

2018-09-06

Svojstava lijeka

_Novocol Pharmaceutical of Canada, Inc._
Page
1
of
23
PRODUCT MONOGRAPH
MARCAINE®
(BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP)
BUPIVACAINE HYDROCHLORIDE 0.5% AND EPINEPHRINE 1:200,000
_Local Anaesthetic for Dental Use _
Sponsor:
Manufacturer:
Carestream Health Canada Company Novocol Pharmaceutical of Canada,Inc.
8800 Dufferin Street 25 Wolseley Court,
Suite 201 Cambridge, Ontario,
Vaughan ON L4K 0C5 N1R 6X3
Date of Revision:
December 2, 2011
Submission Control No: 150074
_Novocol Pharmaceutical of Canada, Inc._
Page
2
of
23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................................3

SUMMARY PRODUCT INFORMATION
....................................................................................................3

INDICATIONS AND CLINICAL
USE..........................................................................................................3

CONTRAINDICATIONS
...............................................................................................................................3

WARNINGS AND
PRECAUTIONS..............................................................................................................4

ADVERSE REACTIONS
...............................................................................................................................7

DRUG
INTERACTIONS................................................................................................................................8

DOSAGE AND
ADMINISTRATION............................................................................................................9

OVERDOSAGE
............................................................................................................................................11

ACTION AND CLINICAL PHARMACOLOGY
........................................................................................13

STORAGE AND STABILITY
...........................................................